– Strong balance sheet of ~$400 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025
– Enrolling MTAP-deletion solid tumors patients into the IDE397 Phase 1 dose escalation and tumor biopsy cohorts;…
